Inhibition of CCAAT/enhancer binding protein δ expression by chrysin in microglial cells results in anti-inflammatory and neuroprotective effects.
The control of neuroinflammation is a potential target to be considered in the treatment of neurodegenerative diseases. It is therefore important to find anti-inflammatory drugs and study new targets that inhibit neuroinflammation. We designed an experimental model of neuroinflammation in vitro to study the anti-inflammatory and neuroprotective effects of the flavonoid chrysin and the involvement of nuclear factor-κB p65 and CCAAT/enhancer binding proteins (C/EBPs) β and δ transcription factors in its mechanism of action. We used primary cultures of mouse embryonic cortical neurons and cultures of BV2 (murine microglial cell line) or mouse primary microglia. We induced neuronal death in neuronal-BV2/microglial co-cultures using lipopolysaccharide of Escherichia coli and interferon-γ. Chrysin pre-treatment inhibited nitric oxide and tumor necrosis factor-α production, as well as inducible nitric oxide synthase expression in lipopolysaccharide E. coli and interferon-γ-treated microglial cells, but did not affect cyclooxygenase-2 expression. Chrysin pre-treatment also protected neurons against the neurotoxicity induced by reactive microglial cells. These effects were associated to a decrease in C/EBPδ protein level, mRNA expression, and DNA-binding activity, with no effect on C/EBPβ and p65 nuclear protein levels or DNA-binding activity, pointing out C/EBPδ as a possible mediator of chrysin effects. Consequently, C/EBPδ is a possible target to act against neuroinflammation in neurodegenerative processes.
Gresa-Arribas
Núria
N
Department of Cerebral Ischemia and Neurodegeneration, Institut d'Investigacions Biomèdiques de Barcelona-Consejo Superior de Investigaciones Científicas (CSIC), Barcelona, Spain.
Serratosa
Joan
J
Saura
Josep
J
Solà
Carme
C
D000818:Animals; D000831:Animals, Newborn; D022763:CCAAT-Enhancer-Binding Protein-alpha / Q000235:genetics / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D018920:Coculture Techniques / Q000379:methods; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism; D004347:Drug Interactions; D004622:Embryo, Mammalian; D005419:Flavonoids / Q000494:pharmacology*; D005786:Gene Expression Regulation / Q000187:drug effects*; D007371:Interferon-gamma / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D017628:Microglia / Q000187:drug effects* / Q000378:metabolism; D016328:NF-kappa B / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D009474:Neurons / Q000187:drug effects / Q000502:physiology; D014162:Transfection / Q000379:methods
D022763:CCAAT-Enhancer-Binding Protein-alpha; D017362:Cyclic AMP Response Element-Binding Protein; D005419:Flavonoids; D008070:Lipopolysaccharides; D016328:NF-kappa B; D009419:Nerve Tissue Proteins; C043561:chrysin; D007371:Interferon-gamma